Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas

International Journal of Oncology

Volumn 14, Issue 6, 1999, Pages 1111-1116

  Alleyne Jr , Cargill H ^a,d   He, Ju ^a   Yang, Jing ^a,e   Hunter, Stephen B ^a   Cotsonis, George ^b   James, C David ^a,f   Olson, Jeffrey J ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY CLINIC   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Brain neoplasm; Cyclin dependent kinase inhibitor; Malignant astrocytoma; p16; p21; p27

Indexed keywords

CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN P16INK4A; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; AUTORADIOGRAPHY; BIOSYNTHESIS; BRAIN TUMOR; CHILD; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; AUTORADIOGRAPHY; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS;

EID: 0033144001     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.6.1111     Document Type: Article

References (49)

1. Nurse P: Ordering S-phase and M-phase in the cell cycle. Cell 79: 547-550, 1994.
2. Clurman BE and Roberts JM: Cell cycle control: an overview. In: The Genetic Basis of Cancer. Vogelstein B and Kinzler KW (eds). McGraw-Hill, New York, pp 175-191, 1998.
3. He J, Olson JJ and James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833-4836, 1995.
4. Winston JT and Pledger WJ: Growth factor regulation of cyclin D1 mRNA expression through protein synthesis-dependent and -independent mechanisms. Mol Biol Cell 4: 1133-1144, 1993.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
6. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR and Vogelstein B: Increased expression of the epidermal growth factor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903, 1987.
7. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, De Fazio A, Watts CK, Musgrove EA and Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133, 1993.
8. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH and Weinstein IB: Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52: 2980-2983, 1992.
9. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A and Peters G: D11S128, a putative oncogene on chromosome 11q13 is amplified and expressed in squamous cell and mammary carcinomas and lined to BCL-1. Oncogene 6: 439-444, 1991.
10. Tsurata H, Sakamoto H, Onda M and Terada M: Amplification and overexpression of EXP1 and EXP2/cyclin D1 genes in human esophageal carcinomas. Biochem Biophys Res Commun 196: 1529-1536, 1993.
11. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbut R, Day RS III and James CD: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804-5807, 1994.
12. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS and Collins VP: Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54: 4299-4303, 1994.
13. Khatib ZA, Matsushime MV, Vlentine M, Shapiro DN, Sherr CJ and Look AT: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53: 5535-5541, 1993.
14. Meyerson M and Harlow E: Identification of a G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14: 2077-2086, 1994.
15. Matsuoka M, Kato J, Fisher RP, Morgan DO and Sherr CJ: Activation of cyclin-dependent kinase 4 (CDK4) by mouse MO15-associated kinase. Mol Cell Biol 14:7265-7275, 1994.
16. PSKJ3/CDK4) for mammalian D-type G1 cyclins. Cell 71: 323-334, 1992.
17. Hinds PW and Weinberg RA: Tumor suppressor genes. Curr Opin Genet Dev 4: 135-141, 1994.
18. Kevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429, 1992.
19. Sherr CJ: The ins and outs of RB: coupling gene expression to the cell cycle clock. Trends Cell Biol 4: 15-18, 1994.
20. Harper JW, Adami GR, Wei N, Keyomarsi K and Ellege SJ: The p21 cdk-interacting protein Cip1 ia a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
21. Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90-98, 1994.
22. INK4/MTS1 tumor suppressor gene product. EMBO J 14: 503-511, 1995.
23. Pietenpol JA, Bohlander SK, Saito Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD and Vogelstein B: Assignment of the human p27kip1 gene 12p1 and its analysis in leukemias. Cancer Res 55: 1206-1210, 1995.
24. Ponce-Casteneda MV, Lee MH, Latres E, Polyak K, Lancombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J and Cordon-Cardo C: p27Kip1 chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55: 1211-1214, 1995.
25. Carlson BA, Dubay MM, Sausville EA, Brizuela L and Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996.
26. Parker BW, Kaur G, Nieves-Neira W, Tiami M, Kohlhagen G, Shimizu T, Pommier Y, Sausville EA and Senderowicz AM: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 15: 458-465, 1998.
27. Patel V, Senderwicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintilla-Martinez L, Ensely JF, Sausville EA and Gutkind JS: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 102: 1674-1681, 1998.
28. Senderowicz AM, Headlee D, Stinson S, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG and Sausville EA: A phase I trial of flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16: 2986-2999, 1998.
29. KIP1. J Clin Invest 97: 1983-1988, 1996.
30. Kamb A, Gruis NA, Weaver-Felhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
31. INK/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8: 2939-2952, 1994.
32. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/cdk4. Nature 366: 704-707, 1993.
33. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW and Volgelstein B: WAF1, a potential mediator of p53 tumor supression. Cell 75: 817-825, 1993.
34. Musunuru K and Hinds PW: Cyclin-CDK regulation: checkpoints and inhibitors. In: Cell Cycle Regulators in Cancer. Karger Landes, Basel, pp70-93, 1997.
35. Ghosh M, Dinda A, Chattopadhyay P, Sarkar C, Bhatia S and Sinha S: Rearranged p53 gene with loss of normal allele in a low-grade non-recurrent glioma. Cancer Genet Cytogenet 78: 68-71, 1994.
36. Rasheed BK, McLendon RE, Herdon JE, Friedman HS, Friedman AH, Bigner DD and Bigner SH: Alterations of the TP53 gene in human gliomas. Cancer Res 54: 1324-1330, 1994.
37. Tabuchi K, Fukayama K, Mineta T, Oh-Uchida M and Hori K: Altered structure and expression of the p53 gene in human neuroepithelial tumors. Neurol Med Chir 32: 725-732, 1992.
38. Zhang S, Feng X, Koga H, Ichikawa T, Abe S and Kumanishi T: p53 gene mutations in pontine gliomas of juvenile onset. Biochem Biophys Res Commun 196: 851-857, 1993.
39. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
40. Xiong Y, Zhang H and Beach D: Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7: 1572-1583, 1993.
41. Zhang H, Xiong Y and Beach D: Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 4: 897-906, 1993.
42. Flores-Rozas H, Kelman Z, Dean FB, Pan Z, Harper WJ, Ellege SJ, O'Donnell M and Hurwitz J: Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase and holoenzyme. Proc Natl Acad Sci USA 91: 8655-8659, 1994.
43. Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
44. Bulrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL, Chiorazzi N, Koff A, Huebner K, Croce CM and Giordano A: Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res 55: 1199-1205, 1995.
45. Firpo E, Koff A, Solomon M and Roberts J: Inactivation of a Cdk2 inhibitor during interleukin-2 induced proliferation of human T lymphocytes. Mol Cell Biol 14: 4889-4901, 1994.
46. Kip1) of cyclin-dependent kinase-4 activation. Cell 79: 487-496, 1994.
47. Polyak K, Lee M, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massague J: Cloning of p27, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994.
48. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
49. Belluco C, Esposito G, Bertorelle R, Del Mistro A, Fassina A, Vicceli G, Chieco-Bianchi L, Nitti D and Lise M: Absence of the cell cycle inhibitor p27Kip1 protein inhibits poor outcome in patients with stage I-III colorectal cancer. Ann Surg Oncol 6: 19-25, 1999.